Leerink is arguably the best when it comes to valuing assets of a pharmaceutical nature. The reason is MEDACorp, a network of 30,000 healthcare professionals that share their knowledge with Leerink.
I find it quite a telling Pfizer's management is meeting with Leerink on the day Amarin gets NOA for combo. Then we open with 2 million shares traded...